These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 36579950)

  • 1. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
    Goyenvalle A; Jimenez-Mallebrera C; van Roon W; Sewing S; Krieg AM; Arechavala-Gomeza V; Andersson P
    Nucleic Acid Ther; 2023 Jan; 33(1):1-16. PubMed ID: 36579950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Safety Assessment of Therapeutic Oligonucleotides.
    Andersson P
    Methods Mol Biol; 2022; 2434():355-370. PubMed ID: 35213031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
    Hirabayashi Y; Maki K; Kinoshita K; Nakazawa T; Obika S; Naota M; Watanabe K; Suzuki M; Arato T; Fujisaka A; Fueki O; Ito K; Onodera H
    Nucleic Acid Ther; 2021 Apr; 31(2):114-125. PubMed ID: 33470890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice.
    Echevarría L; Goyenvalle A
    Methods Mol Biol; 2022; 2434():371-384. PubMed ID: 35213032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
    Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
    Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.
    Frazier KS
    Toxicol Pathol; 2015 Jan; 43(1):78-89. PubMed ID: 25385330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics.
    Zhou H; Arechavala-Gomeza V; Garanto A
    Nucleic Acid Ther; 2023 Aug; 33(4):238-247. PubMed ID: 37145922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Antisense Oligonucleotides Are Coming of Age.
    Bennett CF
    Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S; Kandimalla ER
    Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.